A5019247161- Health Systems, Economic Evaluations, Quality of Life
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Colorectal Cancer Treatments and Studies
- Gallbladder and Bile Duct Disorders
- Cardiac Ischemia and Reperfusion
- Chronic Lymphocytic Leukemia Research
- Pharmaceutical Economics and Policy
- Gastric Cancer Management and Outcomes
- Multiple and Secondary Primary Cancers
- Clostridium difficile and Clostridium perfringens research
- Genetic factors in colorectal cancer
- Biosimilars and Bioanalytical Methods
- Antibiotic Use and Resistance
- Acute Lymphoblastic Leukemia research
- Hematopoietic Stem Cell Transplantation
- Renal Transplantation Outcomes and Treatments
- Economic and Financial Impacts of Cancer
- Prostate Cancer Treatment and Research
- Cardiac Structural Anomalies and Repair
- Breast Implant and Reconstruction
- Gender Politics and Representation
- Neutropenia and Cancer Infections
- Abdominal Surgery and Complications
- Delphi Technique in Research
- Chemical Reaction Mechanisms
Wayne State University
2024
Ono Pharmaceutical (United States)
2022
Research & Development Institute
2022
Levine Cancer Institute
2017-2021
Carolinas Healthcare System
2017
RTI Health Solutions
2015
University of Maryland, Baltimore
2010-2014
University of California, Riverside
2001-2010
National Heart Lung and Blood Institute
2004
Ralph H. Johnson VA Medical Center
2004
Study Objective To estimate the cost‐effectiveness of genotype‐guided selection antiplatelet therapy compared with selecting clopidogrel or prasugrel irrespective genotype. Design Decision model based on event occurrence in Trial to Assess Improvement Therapeutic Outcomes by Optimizing Platelet Inhibition Prasugrel–Thrombolysis Myocardial Infarction ( TRITON ‐ TIMI ) 38. Patients Simulated cohort patients acute coronary syndrome scheduled undergo percutaneous intervention PCI ), consisting...
To evaluate medical policy determinations for pharmacogenetic (PGx) testing 65 clinically relevant drug-gene pairs and evidence cited to support across major US health plans laboratory benefit managers (LBMs). Landscape analysis of available PGx policies determine coverage status certain pairs. as February 1, 2024, were ascertained through Policy Reporter top national insurers, LBMs, the Palmetto GBA Molecular Diagnostic Services (MolDX) Program, which determines whether a molecular...
There is a high risk of voriconazole failure in those with subtherapeutic drug concentrations, which more common CYP 2C19 (cytochrome P450 2C19) rapid/ultrarapid metabolizers ( RMs / UM s). We evaluated genotype‐guided dosing on concentrations and clinical outcomes adult allogeneic hematopoietic cell transplant recipients. Poor PM s), intermediate IM normal NM s) received 200 mg twice daily; s 300 daily. Steady‐state trough were obtained after 5 days, targeting 1.0–5.5 mg/L. Of 89 evaluable...
Abstract Among older individuals diagnosed with metastatic colon cancer (m CC ) there is limited evidence available that describes the characteristics associated advancing to second‐ and subsequent lines of treatment chemotherapy/biologics. Our objective was describe trends received among elderly m patients. Elderly beneficiaries from 2003 2007 were identified in Surveillance, Epidemiology End Results ( SEER )‐Medicare dataset. Beneficiaries followed up until death or censoring. Treatment...
Abstract With new agents entering the market, sequencing of first‐line (Tx1), second‐line (Tx2), and subsequent chemotherapy/biologics regimens are being examined. We examined how Tx1 impacted likelihood receiving Tx2 among metastatic colon cancer ( mCC ) patients. Surveillance, Epidemiology End Results (SEER)‐Medicare data were used to identify elderly patients between 2003 2007. The inverse probability weighting Cox regression method was utilized study relationship receipt regimens,...
Abstract Background Limited data are available regarding second‐line (2 L) treatment for advanced or metastatic biliary tract cancers (BTC) in the US real‐world setting. This study explores rapidly evolving and growing landscape 2 L setting BTC with a large cohort of patients treated community oncology Methods Adult initiating after platinum‐containing first‐line between 1/1/10‐ 6/30/19 were identified from Oncology Network electronic healthcare record database followed through 12/31/19....
Abstract The growing number of older adults within state prisons presents unique challenges and opportunities for gerontological research. To conduct research with this population, however, scholars must navigate a range ethical issues to studying vulnerable group. purpose presentation is delve into the considerations Institutional Review Board (IRB) requirements crucial conducting population. Using examples from our current multisite study on chronic disease self-management among...
Aim: Heterogeneity of treatment effect (HTE) occurs when patient factors modify a treatment’s on health outcomes due to interactions between these and the treatment. This article reviews evidence regarding HTE in stage IV prostate cancer (S4PC). Method: A systematic literature review was conducted MEDLINE PubMed databases. Inclusion criteria required that articles examine treatment-related impact survival, adverse events or health-related quality life S4PC patients. The graded good, fair...
Administration of plerixafor with granulocyte-colony stimulating factor (G-CSF) mobilizes CD34+ cells much more effectively than G-CSF alone, but cost generally limits use to patients at high risk insufficient cell collection based on low peripheral blood (PB) counts following 4 days G-CSF. We analyzed costs associated administering higher day decrease apheresis and explored the a fixed split dose instead weight-based dosing. 235 plasma disorders or non-Hodgkin's lymphoma who underwent...
e15108 Background: HTE occurs when patient factors modify a treatment’s effect on health outcomes so patients in the same study have different responses to specific treatment. Variation is caused by interactions between causing and may explain some of heterogeneity S4PC prognosis. The literature evolving; hence are not yet documented. Methods: A systematic review (1946-2011) published trials observational studies identified evidence statistically significant influencing S4PC. Inclusion...
Hyperkalemic cardioplegic arrest (HCA) and rewarming evokes postoperative myocyte contractile dysfunction, a phenomenon of particular importance in settings preexisting left ventricular (LV) failure. Caspases are intracellular proteolytic enzymes recently demonstrated to degrade myocardial proteins. This study tested the hypothesis that dysfunction induced by HCA could be ameliorated with caspase inhibition setting compromised function. LV myocytes were isolated from control pigs (n = 9, 30...
180 Background: HTE occurs when individual patient factors modify a treatment’s effect on health outcomes in non-random and predictable manner. results specific subgroups of patients the same study having different responses to treatment due interactions between their treatment. Methods: A systematic literature review was conducted articles published 1946 2011. Inclusion criteria required that examine impact survival (OS, TTP, PFS) or QOL among S4PC patients, context The quality evidence...
Co-surgeon approach for bilateral mastectomy may lead to shorter operative times and improved outcomes compared with single-surgeon approach, but cost differences remain unclear. Economic models were applied determine whether either offered a lower opportunity.A retrospective review of 409 patients undergoing or co-surgeon between January 1, 2010 through April 30, 2016 was conducted. Outcomes included narcotic antinausea doses, length stay (LOS), time. Analyses stratified by reconstruction...
Aim: Biliary tract cancers are aggressive, with poor prognosis. This study describes clinical characteristics, treatment patterns and healthcare resource utilization in patients metastatic biliary cancer Japan. Materials & methods: cohort-based collected data from the Japan Medical Data Center claims database (2014-2018). Results: A total of 325 were included; 65.2% male mean age was 59.2 years. 47.6% had an Elixhauser Comorbidity Index score ≥5. Most frequent regimens gemcitabine +...
588 Background: The prognosis for elderly patients with metastatic colon cancer (mCC) is poor 5-year survival rate of 6 %. There limited evidence to explain why some mCC progress through multiple lines treatment and others similar clinical characteristics do not. This study examines the predictors second- third-line chemotherapy receipts in Medicare beneficiaries who initiate treatment. Methods: Using SEER-Medicare dataset, diagnosed from 2003-2007, were followed until death or censoring...
592 Background: Metastatic colon cancer (mCC) patients might receive multiple lines of chemotherapy to improve survival or quality life. However, factors associated with receipt 1 st and 2 nd line treatment (TX) haven’t been fully investigated. Methods: Elderly (65+) SEER-Medicare diagnosed mCC in 2003-2007 were followed until death 12/31/2009 examine for TX. A Cox regression framework inverse probability weighting (IPW) method used adjust patients’ informative (death) non-informative...